Drug Profile
QR 334
Latest Information Update: 16 Nov 2005
Price :
$50
*
At a glance
- Originator Quigley Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sialorrhoea
Most Recent Events
- 09 Nov 2005 Discontinued - Phase-II for Sialorrhoea in USA (unspecified route)
- 22 Jul 2002 Phase-II clinical trials in Sialorrhoea in USA (unspecified route)